{"id":735644,"date":"2025-03-13T06:48:01","date_gmt":"2025-03-13T06:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=735644"},"modified":"2025-03-13T06:48:01","modified_gmt":"2025-03-13T06:48:01","slug":"psoriasis-vulgaris-treatment-market-2032-clinical-trials-ema-pdma-fda-approvals-drugs-market-prevalence-medication-statistics-therapies-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-vulgaris-treatment-market-2032-clinical-trials-ema-pdma-fda-approvals-drugs-market-prevalence-medication-statistics-therapies-companies-by-delveinsight_735644.html","title":{"rendered":"Psoriasis Vulgaris Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/03\/1741681502.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriasis Vulgaris Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/03\/1741681502.jpg\" alt=\"Psoriasis Vulgaris Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Psoriasis Vulgaris Treatment Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Psoriasis Vulgaris companies such as Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma, and others are working in the Psoriasis Vulgaris market.<\/div>\n<p style=\"text-align: justify;\">(Albnay, USA) DelveInsight&#8217;s <strong>Psoriasis Vulgaris Market Insights<\/strong> report proffers a detailed comprehension of the Psoriasis Vulgaris market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Psoriasis Vulgaris market size from 2019 to 2032 segmented into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan).<\/p>\n<p style=\"text-align: justify;\">The Psoriasis Vulgaris market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Psoriasis Vulgaris market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Psoriasis Vulgaris treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Psoriasis Vulgaris market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Psoriasis Vulgaris Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the salient features from the Psoriasis Vulgaris Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Psoriasis Vulgaris is a vibrant type of umbrella indication of Psoriasis. As per DelveInsight&#8217;s assessment, the market for Psoriasis is supposed to advance upto <strong>USD 25,260 million<\/strong> by <strong>2032.<\/strong><\/li>\n<li>DelveInsight analysts suggested that the Psoriasis Vulgaris market size is expected to increase drastically owing to the launches of several potential emerging therapies during the study period.<\/li>\n<li>Key pharmaceutical Psoriasis Vulgaris companies such as <strong>Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma,<\/strong> and others are reported to bring a significant shift in the Psoriasis Vulgaris.<\/li>\n<li>The Psoriasis Vulgaris emerging therapies that are expected to launch in the forecast period include <strong>DMB-3115, Deucravacitinib, BAT2306, <\/strong>and others.<\/li>\n<li>As per DelveInsight&#8217;s analysis approximately <strong>15 million<\/strong> people worldwide have psoriasis, including around 8 million people in the US and more than<strong> 6 million<\/strong> people in EU5. About 80% of those patients suffer from Psoriasis Vulgaris.<\/li>\n<li>Despite drug development advances in the past decade, patient survey data suggest that moderate-to-severe Psoriasis Vulgaris is being undertreated.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the market impact by therapies, download the Psoriasis Vulgaris sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/plaque-psoriasis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Psoriasis Vulgaris Therapeutic Scenario<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Vulgaris Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Psoriasis vulgaris, or plaque psoriasis, is a chronic autoimmune skin disorder characterized by red, scaly, and inflamed plaques that commonly appear on the scalp, elbows, knees, and lower back. It occurs when the immune system mistakenly triggers rapid skin cell turnover, causing an excessive buildup of skin cells.<\/p>\n<p style=\"text-align: justify;\">The exact cause remains unknown, but genetics, immune dysfunction, and environmental factors play key roles. Psoriasis vulgaris Triggers include stress, infections, medications (e.g., beta-blockers, NSAIDs), smoking, alcohol, and cold weather.<\/p>\n<p style=\"text-align: justify;\">Common Psoriasis vulgaris symptoms include itching, burning, and skin cracking, which can significantly impact quality of life. Some patients also develop psoriatic arthritis, causing joint pain and stiffness.<\/p>\n<p style=\"text-align: justify;\">Psoriasis vulgaris Treatment options range from topical therapies (steroids, vitamin D analogs), phototherapy, systemic medications (methotrexate, cyclosporine), and biologic drugs targeting inflammatory pathways like TNF-&alpha;, IL-17, and IL-23 inhibitors.<\/p>\n<p style=\"text-align: justify;\">While no cure exists, lifestyle modifications, such as moisturizing, stress management, and avoiding triggers, help manage symptoms. Early diagnosis and personalized treatment are crucial for minimizing flares and improving skin health.<\/p>\n<p style=\"text-align: justify;\">For severe cases, biologics have revolutionized treatment, offering long-term control and better patient outcomes. Regular follow-ups with dermatologists and rheumatologists ensure effective disease management.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Vulgaris Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">As per the assessment of DelveInsight, Psoriasis is the most common inflammatory disease in the United States, affecting as many as 8 million Americans and this number is expected to increase during the study period.<\/p>\n<p style=\"text-align: justify;\">As per DelveInsight&#8217;s estimates, the total diagnosed prevalent cases of Psoriasis Vulgaris in the US are estimated to be more than <strong>6 million<\/strong> in 2021, the highest among the 7MM and are predicted to increase during the study period (2019-2032).<\/p>\n<p style=\"text-align: justify;\">It is observed that about <strong>80-90%<\/strong> of people living with psoriasis experience Psoriasis Vulgaris and approximately <strong>20%<\/strong> of people suffering from Psoriasis have moderate-to-severe Psoriasis Vulgaris.<\/p>\n<p style=\"text-align: justify;\">The <strong>Psoriasis Vulgaris Market<\/strong> report offers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalent Cases of Psoriasis Vulgaris<\/li>\n<li>Gender-specific Prevalent Cases of Psoriasis Vulgaris<\/li>\n<li>Age-specific Cases of Psoriasis Vulgaris<\/li>\n<li>Severity-specific Prevalence of Psoriasis Vulgaris<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Keen to learn how Psoriasis Vulgaris Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Psoriasis Vulgaris Prevalence<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Vulgaris Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">Although Psoriasis Vulgaris cannot be permanently cured, therapeutic interventions for localized Psoriasis Vulgaris should begin with <strong>patient education<\/strong> and the use of<strong> topical corticosteroids <\/strong>with or without coal tar or calcipotriene. Thereafter, <strong>anthralin <\/strong>or <strong>tazarotene<\/strong>, alone or in combination with steroids, can be used following first-line treatment failure or subsequent loss of response to first-line therapy. Alternatively, if control is difficult to achieve or disease is widespread, <strong>phototherapy<\/strong>, with and without drugs such as <strong>psoralen <\/strong>or <strong>retinoids<\/strong>, may be required.<\/p>\n<p style=\"text-align: justify;\">There are many FDA-approved Psoriasis Vulgaris treatment therapies available in the market. Some of these include <strong>Skyrizi <\/strong>produced by <strong>AbbVie <\/strong>which was approved by the FDA in <strong>April 2019<\/strong> for the treatment of moderate-to-severe plaque psoriasis in adults. <strong>Ilumya <\/strong>is manufactured by <strong>Sun Pharma<\/strong> (also known by its generic name tildrakizumab-asmn), it was FDA approved in <strong>March 2018 <\/strong>for moderate-to-severe Psoriasis Vulgaris treatment in adults. Then, <strong>Johnson &amp; Johnson&#8217;s<\/strong> Psoriasis Vulgaris treatment drug namely <strong>Tremfya <\/strong>(also known by its generic name guselkumab) was FDA approved in <strong>July 2017. <\/strong>Other FDA-approved and currently marketed Psoriasis Vulgaris treatment drugs include <strong>Cimzia <\/strong>by <strong>UCB, Inc., Taltz <\/strong>(ixekizumab) by<strong> Eli Lilly and Company, and Cosentyx <\/strong>(secukinumab) by <strong>Novartis Pharmaceuticals<\/strong>, and <strong>Otezla <\/strong>(apremilast) from <strong>Amgen<\/strong>.<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Psoriasis Vulgaris market are anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several Psoriasis Vulgaris pipeline therapies such as <strong>DMB-3115, Deucravacitinib, BAT2306, <\/strong>and others under investigation by key Psoriasis Vulgaris market players such as <strong>Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma,<\/strong> and many others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapy set to grab substantial Psoriasis Vulgaris market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/plaque-psoriasis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Psoriasis Vulgaris Treatment Market <\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Vulgaris Market Dynamics<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s analysts estimate that the Psoriasis Vulgaris market is poised to show significant growth in the coming years, mainly attributed to<strong> increasing cases, recent drug approvals, <\/strong>and the <strong>anticipated launch of novel therapies<\/strong> during the forecast period.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Vulgaris Market Driver<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Although topical agents help in providing symptomatic relief, they neither mitigate disease progression nor cure the disease. Hence, there is a <strong>need for more safe and efficacious therapies<\/strong> for localized Psoriasis Vulgaris treatment.<\/li>\n<li>Growing worldwide prevalence<\/li>\n<li>Ongoing research and development activities to identify novel and targeted therapies<\/li>\n<li>Increase in Awareness<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Vulgaris Market Barrier<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Poor adherence and compliance with medications<\/li>\n<li>Entry of generics<\/li>\n<li>Challenging disease in terms of management<\/li>\n<li>Low awareness<\/li>\n<li>High economic burden<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Know which therapy is expected to score the touchdown first @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/plaque-psoriasis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Psoriasis Vulgaris Market Landscape and Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Psoriasis Vulgaris Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period:<\/strong> 2019-32<\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Psoriasis Vulgaris Companies: <\/strong>AbbVie, Sun Pharma, Johnson &amp; Johnson, UCB, Inc., Valeant Pharmaceuticals, Eli Lilly and Company, Novartis Pharmaceuticals, Amgen, Meiji Seika Pharma, Soligenix, Dermavant Sciences, Lipidor AB, and many others.<\/li>\n<li><strong>Key Psoriasis Vulgaris Pipeline Therapies<\/strong>: ME3183, SGX302, Tapinarof, AKP02\/AKVANO, and several others.<\/li>\n<li><strong>Psoriasis Vulgaris Therapeutic Assessment<\/strong>: Psoriasis Vulgaris current marketed and emerging therapies<\/li>\n<li><strong>Psoriasis Vulgaris Dynamics:<\/strong> Psoriasis Vulgaris drivers and barriers<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&#8217;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li>Unmet Needs, KOL&#8217;s views, Analyst&#8217;s views, Psoriasis Vulgaris Access and Reimbursement<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Psoriasis Vulgaris Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Executive Summary of Psoriasis Vulgaris<\/p>\n<p style=\"text-align: justify;\">5. Psoriasis Vulgaris Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">6. Psoriasis Vulgaris: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Diagnosis of Psoriasis Vulgaris<\/p>\n<p style=\"text-align: justify;\">8. Psoriasis Vulgaris Treatment<\/p>\n<p style=\"text-align: justify;\">9. Conclusion for Psoriasis Vulgaris<\/p>\n<p style=\"text-align: justify;\">10. Psoriasis Vulgaris Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">11. Psoriasis Vulgaris Patient Journey<\/p>\n<p style=\"text-align: justify;\">12. Key Endpoints in Psoriasis Vulgaris Clinical Trials<\/p>\n<p style=\"text-align: justify;\">13. Psoriasis Vulgaris Marketed Therapies<\/p>\n<p style=\"text-align: justify;\">14. Psoriasis Vulgaris Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">15. Psoriasis Vulgaris: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">16. Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Psoriasis Vulgaris Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Psoriasis Vulgaris Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Psoriasis Vulgaris SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">21. Psoriasis Vulgaris Unmet Needs<\/p>\n<p style=\"text-align: justify;\">22. Appendix<\/p>\n<p style=\"text-align: justify;\">23. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">24. Disclaimer<\/p>\n<p style=\"text-align: justify;\">25. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriasis-vulgaris-treatment-market-2032-clinical-trials-ema-pdma-fda-approvals-drugs-market-prevalence-medication-statistics-therapies-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/aacr-annual-meeting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/aacr-annual-meeting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriasis-vulgaris-treatment-market-2032-clinical-trials-ema-pdma-fda-approvals-drugs-market-prevalence-medication-statistics-therapies-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Psoriasis Vulgaris Treatment Market Psoriasis Vulgaris companies such as Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma, and others are working in the Psoriasis Vulgaris market. (Albnay, USA) DelveInsight&#8217;s Psoriasis Vulgaris Market Insights report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-vulgaris-treatment-market-2032-clinical-trials-ema-pdma-fda-approvals-drugs-market-prevalence-medication-statistics-therapies-companies-by-delveinsight_735644.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-735644","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/735644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=735644"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/735644\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=735644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=735644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=735644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}